Mazdak Ganjalikhani Hakemi PhD (Isfahan University of Medical Sciences)
Associate professor/Senior researcher, Istanbul Medipol University, Istanbul · Turkey
Editorial leadership for International Journal of Multiple Sclerosis and Related Disorders
Research interests
- Cancer Immunotherapy Rnai Immunology
Biography
Dr. Mazdak Ganjalikhani Hakemi is an Associate Professor and Senior Researcher at Istanbul Medipol University in Istanbul, Turkey, having completed his PhD at Isfahan University of Medical Sciences. His research focuses on immunology and cell-based therapies, with particular emphasis on T helper cell subsets (Th17, Treg), innate lymphoid cells, and their roles in autoimmune diseases, immunodeficiencies, and inflammatory conditions such as asthma, multiple sclerosis, common variable immunodeficiency, and ankylosing spondylitis. He has also investigated mesenchymal stem cell-derived extracellular vesicles as novel cell-free therapeutic approaches, contributing his most-cited work, "Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy" (2020), which has been cited 96 times. With over 20 indexed publications, Dr. Hakemi's work spans molecular mechanisms of immune regulation, cytokine signaling, microRNA modulation, and translational applications in cancer and immunological disorders.
Selected publications
- Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy 2020 cited 96×
- mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients 2021 cited 88×
- Therapeutic effects of extracellular vesicles from human adipose‐derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis 2020 cited 78×
- Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients 2018 cited 50×
- Quercetin potential effects against SARS‐CoV‐2 infection and COVID‐19‐associated cancer progression by inhibiting mTOR and hypoxia‐inducible factor‐1α (HIF‐1α) 2022 cited 36×
- Flt3-ITD mutated acute myeloid leukemia patients and COVID-19: potential roles of autophagy and HIF-1α in leukemia progression and mortality 2022 cited 16×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JSC for your work?
This journal is guided by Mazdak Ganjalikhani Hakemi (Associate professor/Senior researcher, Istanbul Medipol University, Istanbul) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.